Proclaim DRG IPG
ABBOTT MEDICAL · Decision date Sep 23, 2026
What did the FDA approve?
FDA approved supplement S100 to PMA P150004 on September 23, 2026. The supplement covers a material change to the encapsulant used in the printed circuit board assembly during manufacture of the Proclaim Spinal Cord Stimulator, Proclaim Dorsal Root Ganglion stimulator, and Infinity Deep Brain Stimulator Implantable Pulse Generator devices. The applicant is Abbott Medical, and the product code is PMP.
The supplement type is Real-Time Process, and the stated reason is Change Design/Components/Specifications/Material. The decision field is APPR. The source statement does not describe the encapsulant chemistry, the manufacturing step affected, or any testing performed. No safety or effectiveness conclusion is present in the supplied fields.
FDA approval order statement
approval for a material change to the encapsulant used in the printed circuit board assembly (PCBA) during the manufacture of the Proclaim Spinal Cord Stimulator (SCS), Proclaim Dorsal Root Ganglion (DRG) stimulator and Infinity Deep Brain Stimulator (DBS) Implantable Pulse Generator (IPG) devices.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Neurology
- Decision date
- Sep 23, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P150004/S100
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- PMP
- Decision code
- APPR
- Decision date
- Sep 23, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Dorsal root ganglion stimulator for pain relief.
- Applicant
- Abbott Medical
- Product code
- PMP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P150004. Subsequent supplements may change the device or its indications.
FDA decision timeline
P150004 · Original PMA
Axium Neurostimulator System
P150004/S100 received
Application receipt date recorded by FDA.
P150004/S100 · FDA decision
Real-Time Process
P150004/S101 · Related supplement
Dorsal Root Ganglion Stimulation (DRG) EPG
Timeline entries are records held by MedtechLedger for P150004. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150004
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Axium Neurostimulator SystemP150004 | ABBOTT MEDICAL | PMA approval | Feb 11, 2016 | FDA |
Dorsal Root Ganglion Stimulation (DRG) EPGP150004/S101 | ABBOTT MEDICAL | PMA supplement | Oct 28, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 6901 Preston Rd., Plano, TX, 75024
Sources and methodology
- Original FDA record: P150004/S100
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
